NASDAQ
6.47USD
-0.01 (-0.15%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
26.9M
P/E
—
EPS
—
Beta
0.21
52W range
3.636-55
Day range
5.92–6.47
Open
6.34
Prev close
6.48
Volume
10.8K
Avg volume
26.2K
Dividend
0.00
IPO
2022-01-05
https://www.globenewswire.com/news-release/2026/07/14/3326551/0/en/Tevogen-Bio-Announces-2026-Annual-Meeting-of-Stockholders.html · 7/14/2026+0.00
https://www.globenewswire.com/news-release/2026/06/09/3309293/0/en/tevogen-announces-formation-of-a-healthcare-services-initiative.html · 6/9/2026+0.60
https://www.globenewswire.com/news-release/2026/04/27/3281867/0/en/Tevogen-AI-Nears-Completion-of-PredicTcell-Training-Initiates-Commercial-Readiness-and-Debuts-Internal-Application-Portal.html · 4/27/2026+0.80
https://www.globenewswire.com/news-release/2026/03/26/3263295/0/en/Tevogen-Advances-Strategic-CRO-Evaluation-to-Expand-Clinical-Research-Delivery-Capabilities-and-Drive-Revenue-Growth.html · 3/26/2026+0.80
https://www.globenewswire.com/news-release/2026/03/18/3258450/0/en/Tevogen-CIO-and-Head-of-Tevogen-AI-Mittul-Mehta-to-Speak-at-Microsoft-Fabric-Community-Conference-FabCon-2026.html · 3/18/2026+0.60
https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html · 3/6/2026+0.60
https://www.benzinga.com/m-a/26/03/51104662/tevogen-bio-explores-buyout-to-boost-generics-platform · 3/6/2026+0.20
https://www.globenewswire.com/news-release/2025/10/15/3167452/0/en/Tevogen-Updates-on-TVGN-489-Following-Growing-Long-COVID-Patient-Interest.html · 10/15/2025+0.60
https://www.globenewswire.com/news-release/2025/09/19/3153373/0/en/Tevogen-Commends-HHS-for-Addressing-Long-COVID-Emphasizes-TVGN-489-s-Potential-Impact-for-20-Million-Americans.html · 9/19/2025+0.60
https://www.globenewswire.com/news-release/2025/09/10/3148013/0/en/Tevogen-CIO-and-Head-of-Tevogen-AI-Mittul-Mehta-to-Join-Startup-Forum-Panel-at-Databricks-DATA-AI-World-Tour-in-Boston.html · 9/10/2025+0.80
https://www.globenewswire.com/news-release/2025/08/25/3138799/0/en/Tevogen-Sees-Continued-Growth-in-Institutional-Ownership-in-Q2-2025-72-of-Holders-Increased-or-Maintained-Positions.html · 8/25/2025+0.80
https://www.globenewswire.com/news-release/2025/08/22/3137994/0/en/Tevogen-Recognized-in-BINJE-s-BEST-Health-Care-2025-for-Advancing-Health-Equity-and-Sustainable-Biopharma.html · 8/22/2025+1.00
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
